SMi Group have worked closely with an expert speaker panel which includes KOLs from Amal Therapeutics, Amgen, DanDrit Biotech, CureVac and Vaccinogen, to put together an exciting conference agenda for the 3rd annual Cancer Vaccines conference taking place on 15th and 16th September in London UK.
This year's programme will feature a mix of case study led presentations, networking opportunities, an interactive workshop and keynote addresses that have been tailored for an audience of professionals working in the cancer vaccine market from drug design through to clinical trials and treatment.
Key Speakers Include:
Joseph Melenhorst, Director of the Product Development and Correlative Sciences laboratory, University Of Pennsylvania
Tom Lillie, Therapeutic Area Head, Oncology, Amgen Ltd
Alex Karlsson-Parra, CSO, Immunicum AB
Birgit Scheel, Director Program Management Oncology, Curevac GmbH
Harpreet Singh, Managing Director, Founder and CSO, Immatics Biotechnologies GmbH
Christian Ottensmeier, Professor in Experimental Cancer Medicine, University Of Southampton
Madiha Derouazi, CEO, Amal Therapeutics
Eric Leire, CEO, DanDrit Biotech
Why Attend in 2014?
Insight into a Perfect Partnership - University of Pennsylvania and Novartis Collaboration! Hear it here first: Assessing techniques involved in removing a patient's T cells and inserting new genetic material to enable the T cells to attack and kill cancer cells
Assessing Oncolytic Vaccines - Reviewing developments from Amgen and Psioxus Therapeutics
What are the key questions in Cancer Immunotherapy? Professor Christian Ottensmeier attacks this question head on!
Evaluating analytical advances for Cancer Vaccines with an insight from Key Opinion Leaders at Immatics GmbH, Vaccinogen and the University of Southampton
To register or download a brochure www.cancer-vaccinesevent.com
Price: Conference: £1499+vat, Conference and workshop: £2098+vat.
+44 (0)20 7827 6148